Navigation Links
Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
Date:6/9/2008

Results from a 24-week multi-center, randomized, open-label study presented

at ADA 2008

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced data showing that the use of mealtime SYMLIN(R) (pramlintide acetate) injection with basal insulin therapy for 24 weeks resulted in more patients achieving diabetes treatment goals of improved glucose control without weight gain or hypoglycemia compared to the use of rapid-acting insulin (RAI) with basal insulin in patients with type 2 diabetes. The results were detailed in an oral presentation at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions in San Francisco.

"These findings are promising because they suggest that treating a deficiency of the hormone amylin in type 2 diabetes can have a beneficial effect on glucose control even when mealtime insulin is not used," said Matthew Riddle, M.D., Professor of Medicine and Head of the Section of Diabetes, Division of Endocrinology at Oregon Health Sciences University and clinical trial investigator. "The effect of SYMLIN was similar to that of mealtime rapid-acting insulin when either was added to basal insulin treatment in this study, with SYMLIN use resulting in no weight gain and less hypoglycemia."

The study was designed to demonstrate improvement in pre-defined comprehensive diabetes treatment goals that included achieving a target A1C and experiencing no weight gain or episodes of severe hypoglycemia. Among those treated with mealtime SYMLIN, 1 in 3 achieved this composite set of goals while only 1 in 10 patients treated with RAI achieved the same results (30 percent vs. 11 percent; P<0.05). Mild or moderate hypoglycemi
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
5. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
6. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
10. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
11. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...
(Date:5/23/2013)... 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... 2013 Life Science Firm of the Year by the Tech ... honored at the TCM,s 25 th Annual Tech Awards ... Tech Awards Celebration recognizes the leaders and innovators in the ... and the surrounding regions. "We are ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Oct. 25, 2011 CareTech Solutions, an information technology ... 180 U.S. hospitals announced today that the company,s client, ... Detroit Medical Center (DMC), Vanguard Health System (VHS) of ... College of Health Information Management Executives (CHIME) Fall CIO ...
... N.J., Oct. 25, 2011 Ericom Software, a ... solutions, today announced the availability of Ericom AccessNow ... AccessNow HTML5 product family. AccessNow for Enterprise Portals ... within leading enterprise portals, including IBM WebSphere Portal, ...
Cached Medicine Technology:Detroit Medical Center Shares Smart Room Case Study at CHIME 2011 Fall CIO Forum 2Ericom AccessNow™ for Enterprise Portals - Secure, Portal-based, HTML5 Web Access to Windows Applications, Desktops and Services 2Ericom AccessNow™ for Enterprise Portals - Secure, Portal-based, HTML5 Web Access to Windows Applications, Desktops and Services 3
(Date:5/24/2013)... May 24, 2013 ResortQuest Real Estate® ... the Dayna Feher team at the firm’s Bethany Beach ... Delaware resorts her home in 1975. Her real estate ... in all aspects of the real estate business - ... past 12 years, a licensed sales associate. , ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- New research ... thoughts among people with insomnia. Every additional ... a 72 percent drop in the likelihood of ... researchers from the University of Pennsylvania. ... association between sleep duration and suicide risk," study ...
(Date:5/24/2013)... (HealthDay News) -- Drugs commonly used to treat glaucoma ... can interfere with vision, according to a new study. ... are used to reduce eye pressure, have already been ... eye color, the researchers said, suggesting that the new ... Doctors should be conservative when prescribing these drugs, ...
(Date:5/24/2013)... Area homeowners dreaming about owning a hot ... to choose from at factory-direct pricing during the Jacuzzi ... takes place at Emerald Pool and Patio in ... the industry's leading hot tub brand, scheduled the event as ... event will feature popular hot tub models at up to ...
(Date:5/24/2013)... myofibromatosis (IM)a disorder characterized by multiple tumors involving the ... according to researchers from the Icahn School of Medicine ... American Journal of Human Genetics , may lead to ... the only current treatment option is repeated surgical removal ... that develops in infancy or even in utero and ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
... tired, keeps having a high temperature even after recovering ... a differential blood count to try to determine the ... in the laboratory a routine procedure in medical ... white blood cells, are quantitatively and qualitatively assessed. The ...
... "This ESMO-symposium will allow bed-side oriented oncologists to ... All presentations will have a clear focus towards ... the major consequences that new developments in cancer ... Soria, Symposium Co-Chair The ESMO Symposium on ...
... structure known as the amygdala. It is the amygdala which ... not only triggers palpitations or nausea but can also cause ... known about the function of this part of the brain. ... and which of the countless neurons in the amygdaloid region ...
... (HealthDay News) -- Long-term use of vitamin E and C ... a new study finds. "An estimated 20.5 million persons ... of age-related cataract," wrote study author William G. Christen, of ... and colleagues, in a news release. Because oxidative damage ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Many family caregivers ... care for their loved ones and experience high levels of ... their role, says a new study. "The care of ... are facing even greater challenges than other family caregivers," said ...
... Reporter , WEDNESDAY, Nov. 10 (HealthDay News) -- Offering ... offer some protection against the development of the antibodies associated ... of the disease, new research suggests. When Finnish ... 1 diabetes to receive either a regular infant formula, or ...
Cached Medicine News:Health News:Performing blood counts automatically 2Health News:Circuitry of fear identified 2Health News:Study Finds Vitamins E and C Don't Reduce Cataract Risk in Men 2Health News:Family Members Caring for Veterans Sacrifice Their Own Health, Jobs 2Health News:Family Members Caring for Veterans Sacrifice Their Own Health, Jobs 3Health News:Special Infant Formula Might Help Shield Babies from Type 1 Diabetes 2Health News:Special Infant Formula Might Help Shield Babies from Type 1 Diabetes 3Health News:Special Infant Formula Might Help Shield Babies from Type 1 Diabetes 4
Inquire...
... MicroAire Power Assisted Lipoplasty Device uses a 2-mm ... facilitate the movement of the cannula in tissue. ... with more fibrous tissue. That makes the lipoplasty ... will ease your mind to learn that the ...
... scfm/0-29.8 in.hg.@sea level. Incredibly quiet, yet very ... canister systems at one time eliminates the ... procedure. Standard canister set-up is for Abbott ... UL, c-UL and CE marks. Includes a ...
... cohesive is a new term being used today to ... more liquid fill that may have been used in ... new science, this is not new technology cohesive ... describe the sticking together nature of the gel. All ...
Medicine Products: